
Some clinical activity was reported for novel tyrosine kinase inhibitors in previously treated patients with GIST

Five-year PFS results show advantage for niraparib maintenance in patients with advanced ovarian cancer, with no OS benefit

New data provide guidance to personalise treatment in recurrent and metastatic salivary gland cancer
